GENFIT Reports Strong Q1 2026 Revenue Growth Driven by Iqirvo Royalties, Advances Pipeline Across Liver Disease Portfolio
核心洞察
GENFIT reported €9.6 million in Q1 2026 revenue, a more than threefold increase from €2.8 million in the same period of 2025, driven entirely by royalties from Ipsen's sales of Iqirvo® (elafibranor) for primary biliary cholangitis (搜索).
Cash and cash equivalents reached €136.1 million as of March 31, 2026, bolstered by a €17 million commercial milestone payment from Ipsen and a €30 million royalty financing tranche, extending the cash runway beyond 2028.
Nitazoxanide (NTZ/G1090N) received FDA Orphan Drug Designation for acute-on-chronic liver failure (搜索) (ACLF) in March 2026, with a proof-of-concept study planned for the second half of 2026.
GENFIT, a late-stage biopharmaceutical company focused on rare and life-threatening liver diseases, reported first-quarter 2026 financial results and provided a corporate update on May 21, 2026, highlighting robust revenue growth, a strengthened cash position, and steady advancement across its pipeline of therapeutic and diagnostic programs.
Revenue Surge Fueled by Iqirvo Momentum
Revenue for the first three months of 2026 reached €9.6 million, compared to €2.8 million for the same period in 2025. All revenue was attributable to royalties from Ipsen's sales of Iqirvo® (elafibranor) for the second-line treatment of primary biliary cholangitis (搜索) (PBC). Ipsen reported Iqirvo net sales of €78.8 million for the first quarter of 2026, reflecting accelerated sales growth in the United States driven by a higher number of patients and strong launches across European countries.
The commercial trajectory has already delivered tangible financial benefits to GENFIT. Full-year 2025 Iqirvo sales reached US$208 million, triggering the first US$20 million (€17 million) commercial milestone payment to GENFIT one year ahead of schedule. This milestone was collected in early 2026.
Strengthened Financial Position
As of March 31, 2026, GENFIT's cash and cash equivalents totaled €136.1 million, up from €129.5 million at the same point in 2025 and €101.1 million as of December 31, 2025. The increase reflects the €17 million Ipsen milestone payment and a €30 million second installment drawn under the company's Royalty Financing agreement with HCRx (搜索), activated in January 2026.
GENFIT stated that its existing cash is expected to fund operating expenses and capital expenditure requirements beyond the end of 2028, based on current assumptions and programs. This estimation assumes receipt of future commercial milestone payments under the Ipsen agreement and the potential drawdown of a third, optional installment under the Royalty Financing agreement.
Pipeline Progress: ACLF Program Gains Orphan Drug Designation
In March 2026, nitazoxanide (NTZ/G1090N) was granted Orphan Drug Designation by the FDA for the treatment of acute-on-chronic liver failure (搜索) (ACLF). This regulatory milestone follows positive Phase 1 data reported in early 2026 that confirmed a favorable safety profile and demonstrated multi-modal biological activity, supporting continued clinical development across the ACLF disease continuum.
GENFIT plans to initiate a proof-of-concept study with nitazoxanide in the second half of 2026, with data expected in 2027. The company also indicated that a pipeline update on ongoing preclinical research programs — including SRT-015, CLM-022, VS-02-HE, and EViv across the ACLF continuum, as well as VS-01-HAC for urea cycle disorders — is planned for the third quarter of 2026.
Cholangiocarcinoma (搜索) Program Advancing
The Phase 1b study evaluating GNS561 in combination with a MEK inhibitor (MEKi) in KRAS (搜索)-mutated cholangiocarcinoma (搜索) (CCA) is progressing as planned, following encouraging preliminary data. Safety data from initial cohorts are expected in mid-2026, with additional data anticipated in the second half of 2026 following study expansion into additional cohorts.
MASH Diagnostics: NASHnext® Commercial Launch Imminent
GENFIT's non-invasive diagnostic technology for metabolic dysfunction-associated steatohepatitis (搜索) (MASH) is approaching a significant commercial milestone. NASHnext®, a diagnostic test developed and commercialized by Labcorp (搜索) as a Laboratory Developed Test (LDT) under license from GENFIT, leverages the company's proprietary technology to identify patients at risk of progressive MASH and support treatment decision-making.
U.S. Medicare and Medicaid have established a pricing framework for NASHnext®, representing important progress toward potential reimbursement and broader payer adoption. A commercial launch by Labcorp (搜索) is expected in the coming weeks, with initial access enabled through Labcorp's on-demand test menu. GENFIT noted that the MASH therapeutics market accelerated in 2025, with the first approved drug therapy achieving near blockbuster performance of approximately US$1 billion in sales in its first year of commercialization.
Elafibranor Lifecycle Expansion into PSC
Ipsen announced the initiation of the Phase 3 ELASCOPE study evaluating elafibranor in primary sclerosing cholangitis (搜索) (PSC) in early 2026. The PSC market opportunity is estimated to be comparable in size to the second-line PBC market. Subject to successful development and regulatory approval, GENFIT would be eligible to receive additional milestone payments and incremental double-digit royalties. The Phase 3 readout, based on clinical outcomes rather than a surrogate endpoint, is expected around 2031.
Ipsen also confirmed that the ELSPIRE Phase 3 study readout in PBC is expected by the end of 2026.
Corporate Governance
In a separate announcement on June 15, 2026, GENFIT reported that all resolutions recommended by the Board of Directors were approved at the Combined Shareholders Meeting, with the exception of resolution number 26, which was rejected in accordance with the Board's recommendations. The meeting achieved a quorum of 32.13%.